GSK Announces U.S. Regulatory Submission For Sirukumab In Rheumatoid Arthritis

GlaxoSmithKline plc (GSK, GSK.L) said that a Biologics License Application or BLA has been submitted by Janssen Biotech, Inc., (JBI) to the U.S. Food and Drug Administration or FDA, seeking approval of a subcutaneous formulation of sirukumab.

from RTT - Biotech http://ift.tt/2dmDIVG
via IFTTT